Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Small molecule inhibitors targeting the cancers
Guihong Liu, Tao Chen, Xin Zhang, et al.
MedComm (2022) Vol. 3, Iss. 4
Open Access | Times Cited: 87

Showing 1-25 of 87 citing articles:

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Kai Fu, Fachao Xie, Fang Wang, et al.
Journal of Hematology & Oncology (2022) Vol. 15, Iss. 1
Open Access | Times Cited: 177
CARBON DOTS: Bioimaging and Anticancer Drug Delivery
Michał Bartkowski, Yingru Zhou, Mustafa Nabil Amin Mustafa, et al.
Chemistry - A European Journal (2024) Vol. 30, Iss. 19
Open Access | Times Cited: 32
Journey of PROTAC: From Bench to Clinical Trial and Beyond
Kyli Berkley, Julian Zalejski, Nidhi Sharma, et al.
Biochemistry (2025)
Closed Access | Times Cited: 3
Enhancing head and neck tumor management with artificial intelligence: Integration and perspectives
Nian‐Nian Zhong, Hanqi Wang, Xin-Yue Huang, et al.
Seminars in Cancer Biology (2023) Vol. 95, pp. 52-74
Closed Access | Times Cited: 39
Reigniting hope in cancer treatment: the promise and pitfalls of IL-2 and IL-2R targeting strategies
Shan Muhammad, Tao Fan, Yang Hai, et al.
Molecular Cancer (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 38
From signalling pathways to targeted therapies: unravelling glioblastoma’s secrets and harnessing two decades of progress
Brittany Dewdney, Misty R. Jenkins, Sarah A. Best, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 36
Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies
Aimi Syamima Abdul Manap, Aini Athirah Wisham, Fei Wen Wong, et al.
Frontiers in Cell and Developmental Biology (2024) Vol. 12
Open Access | Times Cited: 8
Mechanisms of immune modulation in the tumor microenvironment and implications for targeted therapy
Paulina Czajka‐Francuz, Maria J. Prendes, Arun K. Mankan, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 18
Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition
Hyeonji Yoo, Yeon-Jin Kim, Jinseong Kim, et al.
Molecules (2024) Vol. 29, Iss. 17, pp. 3994-3994
Open Access | Times Cited: 5
Small Molecule Targeting Immune Cells: A Novel Approach for Cancer Treatment
Shilpi Singh, Debashis Barik, Ananta Prasad Arukha, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2621-2621
Open Access | Times Cited: 14
Recent advances in multitarget-directed ligands via in silico drug discovery
Maddeboina Krishnaiah, Bharath Yada, Shikha Kumari, et al.
Drug Discovery Today (2024) Vol. 29, Iss. 3, pp. 103904-103904
Closed Access | Times Cited: 5
Crosstalk between hypoxia-induced pyroptosis and immune escape in cancer: From mechanisms to therapy
Seyed Mohammadmahdi Meybodi, Mahsa Ejlalidiz, Mohammadsadegh Rezaeian Manshadi, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 197, pp. 104340-104340
Open Access | Times Cited: 5
Adenosine and Its Receptors in the Pathogenesis and Treatment of Inflammatory Skin Diseases
Luxia Chen, Lei Xuan, Karsten Mahnke
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 11, pp. 5810-5810
Open Access | Times Cited: 5
Unraveling the Peroxidase Activity in Peroxiredoxins: A Comprehensive Review of Mechanisms, Functions, and Biological Significance
Sana Qausain, Mohd Basheeruddin
Cureus (2024)
Open Access | Times Cited: 5
Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting
Pedram Yadollahi, Kelli A. McCord, Yong Li, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2025)
Open Access
Molecular Chimera in Cancer Drug Discovery: Beyond Antibody Therapy, Designing Grafted Stable Peptides Targeting Cancer
Arpan Chowdhury, Prajesh Shrestha, Seetharama D. Jois
International Journal of Peptide Research and Therapeutics (2025) Vol. 31, Iss. 3
Open Access
In Silico Identification of Spirodioxynaphthalenes as Promising Hsp90 Inhibitors
Adam A. Aboalroub
Research Square (Research Square) (2025)
Closed Access
Translational Advances in Oncogene and Tumor-Suppressor Gene Research
Radoslav Stojchevski, Edward Agus Sutanto, R. Sutanto, et al.
Cancers (2025) Vol. 17, Iss. 6, pp. 1008-1008
Open Access
Cardiovascular Toxicity in Patients Treated for Childhood Cancer: A Scientific Statement From the American Heart Association
Thomas D. Ryan, James E. Bates, Karen E. Kinahan, et al.
Circulation (2025)
Closed Access
RNA-lipid nanoparticle therapeutics for women’s health
Alireza Nomani, Aishwarya Saraswat, Yu Zhang, et al.
Frontiers in Nanotechnology (2025) Vol. 7
Open Access
The Potential of Peptide-Based Inhibitors in Disrupting Protein–Protein Interactions for Targeted Cancer Therapy
Ana Maria Sardinha Afonso, Carlos Cavaleiro, Miguel A. R. B. Castanho, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 7, pp. 3117-3117
Open Access
Alkaloid-Based Modulators of the PI3K/Akt/mTOR Pathway for Cancer Therapy: Understandings from Pharmacological Point of View
Fatima Zohra Mokhfi, Md. Al Amin, Mehrukh Zehravi, et al.
Chemico-Biological Interactions (2024) Vol. 402, pp. 111218-111218
Closed Access | Times Cited: 4
Novel Therapies in APOL1-Mediated Kidney Disease: From Molecular Pathways to Therapeutic Options
George Vasquez‐Rios, Marina de Cos, Kirk N. Campbell
Kidney International Reports (2023) Vol. 8, Iss. 11, pp. 2226-2234
Open Access | Times Cited: 10
Synthetic self‐adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy
Yang Zhou, Xinru Li, Yajing Guo, et al.
MedComm (2024) Vol. 5, Iss. 2
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top